These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 8335038)
1. Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives. Danhof M; Mandema JW; Hoogerkamp A; Mathôt RA Eur J Drug Metab Pharmacokinet; 1993; 18(1):41-7. PubMed ID: 8335038 [TBL] [Abstract][Full Text] [Related]
2. Modelling of the pharmacodynamics and pharmacodynamic interactions of CNS active drugs. Danhof M; Mandema JW Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):516-9. PubMed ID: 1490817 [TBL] [Abstract][Full Text] [Related]
3. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. Mandema JW; Tukker E; Danhof M J Pharmacol Exp Ther; 1992 Jan; 260(1):36-44. PubMed ID: 1309878 [TBL] [Abstract][Full Text] [Related]
4. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296 [TBL] [Abstract][Full Text] [Related]
5. Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society. Cavero I Expert Opin Drug Saf; 2007 Jul; 6(4):465-71. PubMed ID: 17688390 [TBL] [Abstract][Full Text] [Related]
6. Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs. Reife RA Adv Neurol; 1998; 76():95-103. PubMed ID: 9408466 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats. van Schaick EA; de Greef HJ; Langemeijer MW; Sheehan MJ; IJzerman AP; Danhof M Br J Pharmacol; 1997 Oct; 122(3):525-33. PubMed ID: 9351510 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. Cox EH; Kuipers JA; Danhof M Br J Pharmacol; 1998 Aug; 124(7):1534-40. PubMed ID: 9723968 [TBL] [Abstract][Full Text] [Related]
9. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Mandema JW; Danhof M Clin Pharmacokinet; 1992 Sep; 23(3):191-215. PubMed ID: 1511536 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. Kalvass JC; Olson ER; Cassidy MP; Selley DE; Pollack GM J Pharmacol Exp Ther; 2007 Oct; 323(1):346-55. PubMed ID: 17646430 [TBL] [Abstract][Full Text] [Related]
11. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. Lees P; Giraudel J; Landoni MF; Toutain PL J Vet Pharmacol Ther; 2004 Dec; 27(6):491-502. PubMed ID: 15601443 [TBL] [Abstract][Full Text] [Related]
12. Adaptive changes in the pharmacodynamics of midazolam in different experimental models of epilepsy: kindling, cortical stimulation and genetic absence epilepsy. Cleton A; Voskuyl RA; Danhof M Br J Pharmacol; 1998 Oct; 125(4):615-20. PubMed ID: 9831893 [TBL] [Abstract][Full Text] [Related]
13. Current and future directions of pharmacokinetic and pharmacokinetic-pharmacodynamic modelling and simulation: population approach group in Europe 19th annual meeting. Kloft C; Poggesi I Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1599-604. PubMed ID: 20969486 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint. van Steeg TJ; Freijer J; Danhof M; de Lange EC Br J Pharmacol; 2007 Jun; 151(3):356-66. PubMed ID: 17420778 [TBL] [Abstract][Full Text] [Related]
15. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Meibohm B; Derendorf H Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. Della Paschoa OE; Mandema JW; Voskuyl RA; Danhof M J Pharmacol Exp Ther; 1998 Feb; 284(2):460-6. PubMed ID: 9454785 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. Mathôt RA; van Schaick EA; Langemeijer MW; Soudijn W; Breimer DD; Ijzerman AP; Danhof M J Pharmacol Exp Ther; 1994 Feb; 268(2):616-24. PubMed ID: 8113972 [TBL] [Abstract][Full Text] [Related]
18. In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. Mandema JW; Kuck MT; Danhof M J Pharmacol Exp Ther; 1992 Apr; 261(1):56-61. PubMed ID: 1560385 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. Groenendaal D; Freijer J; Rosier A; de Mik D; Nicholls G; Hersey A; Ayrton AD; Danhof M; de Lange EC Eur J Pharm Sci; 2008 Jul; 34(2-3):149-63. PubMed ID: 18467078 [TBL] [Abstract][Full Text] [Related]